N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

U

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Status and phase

Completed
Phase 2

Conditions

Hypotension
Acute Renal Failure

Treatments

Drug: N-acetylcysteine and deferoxamine

Study type

Interventional

Funder types

Other

Identifiers

NCT00870883
FR208621

Details and patient eligibility

About

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

Enrollment

81 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients admitted to the ICU
  • Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion

Exclusion criteria

  • Age lower than 18 years old
  • Chronic renal failure
  • A known history of allergy to any of the study drugs
  • Using n-acetylcysteine to paracetamol overdose
  • Pregnant women
  • Patients who used iodinated contrast medium
  • Hemoglobin less than 6.5 mg/dl
  • Cancer patients

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

81 participants in 1 patient group

N-acetylcysteine plus deferoxamine
Experimental group
Treatment:
Drug: N-acetylcysteine and deferoxamine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems